Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,987 total articles
Standard Lithium just cleared two headline milestones: a binding Trafigura offtake for 8,000 tpa and >$1 billion in project debt indications for the South West Arkansas (SWA) project. The stock is digesting those wins after a pullback; with a sub-$1.0B market cap and clear near-term catalysts, this is a defined-risk, mid-term long trade.
Ternium offers a rare combination of a double-digit yield alternative (7.08% yield), a low price-to-book multiple (PB ~0.63) and cyclical upside if steel demand improves. The stock trades below its short- and medium-term moving averages and shows oversold technicals, creating a disciplined long entry for investors who can tolerate cyclicality and l…
UFP Industries (UFPI) looks attractively priced today. At $90.65 the stock trades at ~18x next-year EPS, EV/EBITDA ~8.3 and a market cap near $5.13B, while generating $276M of free cash flow and carrying almost no net leverage. Technicals show oversold conditions and short interest remains meaningful - a setup for a rebound if the industry stabiliz…
Qualcomm is trading well below its 52-week highs after the sector sell-off, but fundamentals remain intact: high free cash flow ($12.93B), a mid-20s P/E, a 2.7% yield and attractive EV/EBITDA of ~11. I lay out an actionable long trade with entry, stop and target and the reasons I'll keep adding on weakness over a 180-trading-day horizon.
ImmunityBio's Anktiva is transitioning from clinical validation to commercial scale. Recent EU approval, NCCN guideline inclusion and stronger-than-expected sales place upside within reach, but valuation and execution risks are non-trivial. This trade idea lays out an actionable long with entry, stop and targets across a mid-term horizon.
I am upgrading Palantir (PLTR) from Hold to Buy. The combination of sustained AI-driven demand, improving free cash flow ($2.10B trailing), a technically constructive setup, and manageable short interest creates an asymmetric trade opportunity. The valuation is rich, but recent operational proof points and catalysts justify a disciplined swing trad…
Wintrust Financial (WTFC) looks like a practical mid-term long: reasonable valuation (P/E ~12, P/B ~1.26), $1.10B in free cash flow, a freshly raised dividend and an RSI flirting with oversold. We lay out an entry at $130.00, a stop at $122.00 and a $150 target over ~45 trading days, with clear risk management and alternative horizons.
SMH has rallied sharply since last year's lows but remains supported by accelerating semiconductor demand tied to AI infrastructure and equipment spending. With a $44.3B market cap, a 52-week high at $427.94 and technicals sitting near key moving averages, I outline a swing trade to capture additional upside while containing downside with a strict …
MercadoLibre is down after an earnings miss and margin reinvestments, but fundamentals — $10.8B in free cash flow, 37%+ revenue growth cited in recent coverage, and a dominant fintech pipeline — argue for a long entry on weakness. This trade targets a recovery toward prior multiple expansion while keeping a tight stop for downside protection.
Roivant Sciences (ROIV) looks set to re-rate as clinical readouts and corporate de-risking converge. With a market cap near $20.2B, clear near-term catalysts (Q3 2026 rheumatoid arthritis data and continuing progress in the ulcerative colitis program), and improving technicals around rising 50-day support, I view ROIV as a strong buy for a long-ter…
Harrow is moving from niche compounding toward a broad ophthalmic platform. Management reaffirmed 2025 revenue of $270-$280M, is doubling multiple sales forces, and is integrating Melt Pharmaceuticals to extend procedural sedation reach. With heavy short interest and near-term technical oversold signals, this is a tradeable long targeting a re-rati…
Marvell just demonstrated that its role in AI infrastructure is more substantial than many investors realize. Strong fiscal Q4 results, aggressive FY2027 guidance, improving technicals, and a clean balance sheet support a mid-term long trade: entry $91.15, stop $80.00, target $120.00 over the next 45 trading days.
Rayonier's timberland portfolio and recent corporate actions make the stock an actionable swing trade. The market is underpricing the combination of recurring cash flow, a potential special return of capital and merger-driven upside. Entry at $20.25, stop at $19.20 and target at $24.00 for a mid-term trade (45 trading days).
Natera is trading near $200 with multiple oncology catalysts in motion: positive MRD data for Signatera, a strategic acquisition of Foresight Diagnostics, and growing market demand for esoteric and reproductive genetic tests. Fundamentals show improving free cash flow ($109.1M) and low leverage, but valuation is rich (P/S ~12, P/B ~16). This trade …
Kimberly-Clark offers a rare combination in 2026: a ~5% yield, steady free cash flow ($1.639B) and a strategically meaningful, deal-driven catalyst with the planned Kenvue acquisition. Valuation sits at ~16.5x trailing earnings and an enterprise value of roughly $39.8B, leaving room for upside if synergies materialize and pricing power holds. I out…
Broadcom's custom AI chips and networking franchises are powering an accelerating revenue mix; recent quarterly flows and management guidance show the AI cycle is already material to the top line. With $28.9B in annual free cash flow and a market cap near $1.5T, AVGO is expensive but priced for sustained AI-led earnings growth — we recommend a tact…
Micron (MU) is trading with momentum after a strategic fab purchase and ahead of a volatile earnings print. With sold-out HBM capacity through 2026, improving margins, $4.65B in free cash flow, and bullish technicals, the stock looks tradeable on the long side into the next quarter. This plan lays out a mid-term trade (45 trading days) to capture p…
Affirm's share-price consolidation looks like a durable bottom. Gross merchandise volume growth, positive free cash flow and early signs of higher-margin product mix justify a long position. Entry at $48 with a $40 stop and a $75 target gives a risk-reward profile aligned to recovering multiples and operational leverage.
Academy Sports (ASO) reported modest Q4 and fiscal 2025 growth with a return to topline expansion, a 15% dividend bump, and guidance for low-single-digit sales growth. The stock is trading near $51.65 with a P/E below 10 on trailing EPS and EV/EBITDA around 6.4 — attractive on face value. Technicals and negative comps introduce near-term risk. This…
Broadcom (AVGO) is trading off recent highs on scentiment pressure despite accelerating AI revenue and positive analyst commentary. The pullback to $322 offers a defined-risk, mid-term swing with upside tied to continued AI infrastructure demand and an improving multiple as fundamentals prove out.
Coinbase is positioning itself as an 'Everything Exchange'—a single interface for trading, custody, staking, stablecoin services and developer access. At $208 the stock already discounts some volatility. We lay out a long trade with an entry at $205, $260 target and $185 stop, and explain the case, catalysts and balanced risks driving the idea.
Nebius’ five-year, up-to-$27 billion agreement with Meta reframes capacity access for hyperscalers. For Meta, the deal buys predictable AI capacity and shifts some capex into contracted variable spending — a structural plus if Nebius delivers on performance and cost. Combine that with Meta’s strong free cash flow and modest leverage and the stock l…
KKR has been punished alongside peers as private-credit redemption headlines swirl. The selloff has pushed the stock near its 52-week low while underlying cash flow and franchise economics remain intact. This trade idea lays out an actionable mid-term long: entry at $88.21, stop at $82.50, target $105.00 (45 trading days).
AppLovin is expensive on traditional multiples but is showing momentum: strong revenue growth, an AI-driven ad engine narrative, improving technicals, and heavy short interest set the stage for a momentum trade. This idea is a mid-term (45 trading days) long entry on strength with a tight stop to respect the elevated valuation.
Incyte is priced more like a single-commercial product company despite generating meaningful free cash flow, carrying almost no debt, and fielding several late-stage assets. Recent mixed clinical reads have compressed the multiple; we see a trade to capture a re-rating as volatility around Opzelura and povorcitinib settles.
